Clover Corp Ltd (ASX: CLV) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Clover Corp Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Clover Corp Ltd (ASX: CLV)
Latest News
⏸️ Income
3 reasons why Soul Patts (ASX:SOL) is a great ASX dividend share
⏸️ Investor Education
What is a holding company?
Share Fallers
Here's why the Clover (ASX:CLV) share price crashed 20% lower today
⏸️ Dividend Shares
2 ASX dividend shares raising their dividends like clockwork
Growth Shares
2 ASX growth shares I'd buy today for growth and income
⏸️ Dividend Shares
Where I'd invest $10,000 into ASX dividend shares
Speculative
Could these small cap ASX shares be the next Afterpay (ASX:APT) or Zip (ASX:Z1P)?
⏸️ ASX Shares
Is the Soul Patts (ASX:SOL) share price a buy?
ASX Share Market News
Leading brokers name 3 ASX shares to buy today
Share Fallers
Why Byron Energy, Clover, DEXUS, & Webjet shares are sinking lower today
ASX Share Market News
3 ASX growth shares I'd buy today for growth and income
ASX Share Market News
ASX 200 drops 0.3%, gold miners keep rising
Frequently Asked Questions
-
Yes, Clover Corporation has historically paid two fully franked shareholder dividends a year.
-
Clover Corporation generally pays its dividends in April and November.
-
No, Clover Corporation does not have a dividend reinvestment plan at the current time.
-
Clover Corporation listed on the ASX on 30 November 1999.
Dividend Payment History Data provided by Morningstar.
| Ex-Date | Amount | Franking | Type | Payable |
|---|---|---|---|---|
| 20 Oct 2026 | $0.0125 | 100.00% | Final | 19 Nov 2026 |
| 15 Apr 2026 | $0.0100 | 100.00% | Interim | 30 Apr 2026 |
| 20 Oct 2025 | $0.0100 | 100.00% | Final | 20 Nov 2025 |
| 09 Apr 2025 | $0.0075 | 100.00% | Interim | 24 Apr 2025 |
| 21 Oct 2024 | $0.0075 | 100.00% | Final | 18 Nov 2024 |
| 30 Oct 2023 | $0.0075 | 100.00% | Final | 20 Nov 2023 |
| 05 Apr 2023 | $0.0075 | 100.00% | Interim | 27 Apr 2023 |
| 25 Oct 2022 | $0.0100 | 100.00% | Final | 22 Nov 2022 |
| 06 Apr 2022 | $0.0050 | 100.00% | Interim | 28 Apr 2022 |
| 25 Oct 2021 | $0.0050 | 100.00% | Final | 16 Nov 2021 |
| 07 Apr 2021 | $0.0050 | 100.00% | Interim | 29 Apr 2021 |
| 27 Oct 2020 | $0.0250 | 100.00% | Final | 18 Nov 2020 |
| 29 Oct 2019 | $0.0175 | 100.00% | Final | 20 Nov 2019 |
| 08 Apr 2019 | $0.0063 | 100.00% | Interim | 30 Apr 2019 |
| 29 Oct 2018 | $0.0125 | 100.00% | Final | 20 Nov 2018 |
| 09 Apr 2018 | $0.0050 | 100.00% | Interim | 01 May 2018 |
| 27 Oct 2017 | $0.0000 | 100.00% | Final | 20 Nov 2017 |
| 10 Apr 2017 | $0.0025 | 100.00% | Interim | 01 May 2017 |
| 27 Oct 2016 | $0.0050 | 100.00% | Final | 21 Nov 2016 |
| 11 Apr 2016 | $0.0025 | 100.00% | Interim | 02 May 2016 |
| 29 Nov 2010 | $0.0125 | 100.00% | Final | 15 Dec 2010 |
CLV ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Clover Corp Ltd
Clover Corporation Limited (ASX: CLV) provides nutritional ingredients, particularly omega-3 and omega-6 fatty acids. The company is involved in the production of encapsulated powders, and research and product development of infant nutrition and functional food ingredients.
Clover Corporation offers Nu-MegaHi tuna oils for use in infant formula and pharmaceutical products, as well as Ocean Gold refined tuna oils. Its products include DHA oils, DHA powders, and other nutritional oils drawn from patented microencapsulation technologies. Geographically, the group has a business presence in Australia, New Zealand, Asia, Europe, and the Americas. The majority of the company's revenue is derived from the Asian market.
CLV Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 03 Nov 2026 | $0.97 | $0.00 | 0.00% | 71,620 | $0.97 | $0.99 | $0.96 |
| 02 Nov 2026 | $0.97 | $-0.03 | -3.00% | 303,192 | $0.98 | $1.04 | $0.97 |
| 30 Oct 2026 | $1.00 | $0.01 | 1.01% | 101,159 | $1.00 | $1.00 | $0.98 |
| 29 Oct 2026 | $1.00 | $-0.01 | -1.00% | 162,102 | $1.00 | $1.00 | $0.98 |
| 28 Oct 2026 | $1.00 | $0.00 | 0.00% | 728,933 | $1.01 | $1.01 | $1.00 |
| 27 Oct 2026 | $1.01 | $0.02 | 2.03% | 285,326 | $1.00 | $1.01 | $1.00 |
| 26 Oct 2026 | $0.99 | $-0.03 | -2.96% | 431,332 | $1.03 | $1.03 | $0.98 |
| 23 Oct 2026 | $1.02 | $-0.01 | -0.98% | 251,217 | $1.02 | $1.05 | $0.99 |
| 22 Oct 2026 | $1.02 | $0.00 | 0.00% | 112,483 | $1.03 | $1.03 | $0.99 |
| 21 Oct 2026 | $1.03 | $-0.03 | -2.86% | 138,833 | $1.05 | $1.05 | $1.02 |
| 20 Oct 2026 | $1.05 | $0.02 | 1.94% | 143,580 | $1.00 | $1.05 | $1.00 |
| 19 Oct 2026 | $1.03 | $0.01 | 0.98% | 149,397 | $1.01 | $1.05 | $1.01 |
| 16 Oct 2026 | $1.03 | $-0.01 | -0.97% | 1,294,147 | $1.03 | $1.05 | $1.02 |
| 15 Oct 2026 | $1.03 | $0.00 | 0.00% | 313,774 | $1.03 | $1.03 | $1.00 |
| 14 Oct 2026 | $1.03 | $0.01 | 0.98% | 534,550 | $1.03 | $1.04 | $1.03 |
| 13 Oct 2026 | $1.02 | $0.01 | 0.99% | 102,405 | $1.01 | $1.02 | $1.01 |
| 12 Oct 2026 | $1.01 | $0.01 | 1.00% | 83,270 | $1.01 | $1.01 | $0.99 |
| 09 Oct 2026 | $1.00 | $-0.02 | -1.96% | 10,451 | $1.02 | $1.02 | $1.00 |
| 08 Oct 2026 | $1.02 | $-0.01 | -0.97% | 54,652 | $1.03 | $1.03 | $0.98 |
| 07 Oct 2026 | $1.03 | $0.08 | 8.42% | 78,367 | $0.95 | $1.03 | $0.95 |
| 06 Oct 2026 | $0.95 | $-0.05 | -5.03% | 50,000 | $1.00 | $1.00 | $0.95 |
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 28 Oct 2026 | Simon Green | Buy | 10,000 | $10,273 |
On-market trade.
|
| 27 Oct 2026 | Brett Hewlett | Buy | 10,000 | $10,005 |
On-market trade.
|
| 20 Oct 2026 | Ian Glasson | Buy | 50,000 | $51,500 |
On-market trade.
|
| 09 Oct 2026 | Andrew Allibon | Buy | 5,000 | $5,016 |
On-market trade.
|
| 08 Oct 2026 | Fiona Pearse | Buy | 30,827 | $30,049 |
On-market trade.
|
| 08 Oct 2026 | Andrew Allibon | Buy | 22,553 | $22,553 |
On-market trade.
|
| 06 Oct 2026 | Fiona Pearse | Buy | 10,000 | $10,013 |
On-market trade.
|
| 18 Nov 2025 | Peter Davey | Buy | 529,638 | $368,098 |
On-market trade. 16,16,905 Performance Rights
|
| 18 Nov 2025 | Peter Davey | Sell | 255,199 | $177,363 |
On-market trade. 1,361,706 Performance Rights
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Mr Ian David Glasson | Non-Executive Director | Feb 2017 |
Mr Glasson is former CEO of PGG Wrightson based in Christchurch, New Zealand. He was formerly CEO of Gold Coin Group / Zuellig Agriculture which managed a portfolio of animal feed operations and farming ventures throughout South-East Asia. Prior to that he was CEO for seven years of Sucrogen which generated revenues of nearly $2 billion and had contacts across the local and international food and beverage sector and retail market. He has also had agribusiness experience with Goodman Fielder and Gresham Rabo, as well as spending the first sixteen years of his career in the oil and gas sector with Esso. He is the Chair of the People & Culture Committee and a Member of the Risk Committee.
|
| Ms Toni Brendish | Non-Executive Director | Oct 2020 |
Ms Brendish has more than 30 years of experience working in blue chip FMCG, healthcare, manufacturing, agriculture, and telecommunication companies in Asia, Australia, and New Zealand, including over 20 years in Chief Executive Officer / Managing Director roles. Toni's last executive role was as Chief Executive Officer of Westland Milk Products in the South Island of New Zealand. Prior to this, Toni spent 11 years working for the Danone Group as Managing Director of their Infant Formula and Dairy businesses in Australia, New Zealand, Malaysia and Indonesia. She has also worked for Kimberly-Clark and Colgate Palmolive, together with several other blue chip FMCG organizations. She is a member of the Risk, People &
Culture Committees. |
| Mr Rupert Anthony Harrington | Non-Executive DirectorNon-Executive Chairman | Jul 2015 |
Mr Harrington is an experienced company Director with over 30 years of experience as a Non-Executive Director of companies operating in manufacturing, industrial services, health and technology. He has been involved in private equity since 1987 and is one of the founders of the Australian industry
|
| Mr Peter J Davey | Chief Executive OfficerManaging Director | Dec 2014 |
Mr Davey has a record of building businesses across a range of industry sectors. He has held senior management positions within several manufacturing and distribution companies. Mr Davey was formerly Executive Manager AgriProducts and a director of Viterra Australia Limited, responsible for the AgriProducts division that traded in agricultural inputs, fertilizer, seed and wool. In earlier roles, Mr Davey headed the Sales and Marketing divisions of FMP Products and Hi Fert Pty Ltd. During his career, Mr Davey has had a particular focus on marketing-based businesses operating in the Asia and Oceania regions.
|
| Mr Brett Hewlett | Non-Executive Director | Oct 2026 |
Mr Hewlett is a non-executive director who has commercial and engineering expertise having worked internationally with Alfa Laval and Tetra_Pak for 17 years. Most recently Brett was Chairman of Comvita (2020 - 2024), and previously CEO for 10 years. Brett has held non-executive director roles in New Zealand with Comvita (NZX:CVT), Quayside Holdings, Bluelab Inc (board Chair), SeaDragon (NZX:SEA) and in the USA with Derma Sciences Inc (Nasdaq:DSCI).
|
| Dr Simon Green | Non-Executive Director | Oct 2020 |
Mr Green has years of experience in the biotechnology industry focused on the discovery, development and commercialization of life-saving medicines. He was actively involved in CSL's global expansion over a 17-year period and held roles as Senior Vice President, Global Plasma R&D and General Manager of CSL's manufacturing plants in Germany and Australia. Simon is the founder and CEO of Immunosis Pty Ltd, a startup diagnostics Company. He is the Chair of the Innovation & Development
Committee and a Member of the Risk, People & Culture Committee. |
| Ms Fiona Pearse | Non-Executive Director | Aug 2025 |
Ms Pearse is an experienced Non-Executive Director who has commercial expertise obtained from a commercial, finance and tax career during almost two decades at complex listed, global companies. Fiona is the current Chair of the Board of U Ethical, one of Australia's ethical Fund Managers. She is also a Non-Executive Director of Monash Health. She is Chair of the Risk Committee and a Member of the People & Culture Committee.
|
| Mr Andrew Allibon | Chief Financial OfficerCompany Secretary | May 2021 |
-
|
| Andrew Allibon | Chief Financial OfficerCompany Secretary |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| Citicorp Nominees Pty Limited | 29,204,408 | 17.49% |
| HSBC Custody Nominees (Australia) Limited | 21,558,135 | 12.91% |
| UBS Nominees Pty Ltd | 11,726,358 | 7.02% |
| Anacacia Pty Ltd <Wattle Fund A/C> | 9,452,458 | 5.66% |
| Evelin Investments Pty Limited | 7,550,000 | 4.52% |
| J P Morgan Nominees Australia Pty Limited | 7,278,245 | 4.36% |
| Jeremy And Lynette King Superannuation Pty Ltd | 6,000,000 | 3.59% |
| Thorney International Pty Ltd | 3,967,539 | 2.38% |
| King Equity Capital Pty Ltd | 2,361,000 | 1.41% |
| Incani & Papadopoulos Super Pty Ltd | 2,010,000 | 1.20% |
| Sandhurst Trustees Ltd <Millex Ethical Fund A/C> | 2,000,000 | 1.20% |
| Mr Sundeep Kalra & Mr Anoop Kalra & Mrs Shikha Mohanty <Ganesh Super Fund A/C> | 1,747,825 | 1.05% |
| BNP Paribas Noms (Nz) Ltd | 1,549,382 | 0.93% |
| Alex King Family Holdings Pty Ltd <Alex King Family A/C> | 1,500,000 | 0.90% |
| Cpu Share Plans Pty Ltd <Clv Eip Unallocated A/C> | 1,393,457 | 0.83% |
| Dmx Capital Partners Ltd | 1,393,345 | 0.83% |
| Jiva Holdings Pty Ltd <Kalra Family A/C> | 1,217,500 | 0.73% |
| Ray & Dawn Pty Ltd <King Super Fund A/C> | 1,135,367 | 0.68% |
| Mr Garrie Ellice | 960,000 | 0.57% |
| Mrs Malaine Christine Haet | 944,800 | 0.57% |